## CONTENTS

### SECTION 1 HYPERTENSION

1. **Pitfalls in Hypertension Management** ................................................................. 3  
   K Tewary  
   Errors in Examination  3  
   Diagnostic Errors  3  
   Treatment Errors  4  
   Errors by Patients  4

2. **Ambulatory Blood Pressure Monitoring in Clinical Practice** ................................. 6  
   Narayan G Deogaonkar, Viplav N Deogaonkar

3. **Azilsartan: A New Baby in Old Horizon** .............................................................. 17  
   BA Muruganathan  
   Evolution of the Angiotensin II Receptor Blockers  17  
   Angiotensin Receptor Blockers: Beyond Blood Pressure Lowering Effects  18  
   Tolerability  18  
   Direct AT1R Effects of Azilsartan  19  
   Azilsartan: Potent AT1 Receptor Binding  19  
   Azilsartan: Pleiotropic Effects Beyond BP Lowering  19  
   Azilsartan: Potential Effect in Cardio-Renal Protection  20  
   Summary of the Unique Features of Azilsartan  22

4. **Hypertension and Menopause** .............................................................................. 24  
   Anuj Maheshwari, Shipra Kunwar  
   Role of Oxidative Stress and Vasoconstrictors  24  
   Hypertension: The Key Risk Factor during Menopause  26  
   How should It be Treated?  27

5. **Renovascular Hypertension: Current Status** ......................................................... 28  
   Puneet Rijhwani  
   Pathogenesis  28  
   Renovascular Hypertension: Major Causes  28  
   Diagnosis  29  
   Medical Management  30
6. Diuretics for Hypertension: Review and Update
R Rajasekar
- Effect of Low Dose Diuretic
- Types of Diuretics
- Potassium-Sparing Common Combination Diuretics
- Combination of Diuretic with Anti-HT Drugs

7. High Altitude Systemic Hypertension: Unraveling the Mystery
VA Kothiwale, Deebanshu Gupta
- Effects of High Altitude on Cardiovascular System
- Need for Definition of HASH – and Its Prevalence
- Pathophysiology of Hash
- Role of Endothelin 1
- Ageing, High Altitude and Blood Pressure-A Complex Relationship
- Blood Pressure Changes with Aging
- How BP Behaves with Aging in People Chronically Exposed to High Altitude
- Importance of Recognizing Hash
- Diagnosis of HASH
- Treatment of HASH

8. Management of Isolated Systolic Hypertension: Current Concepts
Girish Mathur, Shrikant Chaudhary
- Prevalence and Risk Factor
- Classification of ISH
- Evaluation of ISH
- Management of Hypertension
- Benefits of Treatment of ISH
- Interventional Trial Concerning ISH
- Smaller Studies on ISH

9. Blood Pressure Control with Changing Time
BR Bansode
- Management of Hypertension
- JNC 1974 to 2003 (1 to 7)
- Conclusion and Perspectives
10. Management of Hypertension in Diabetes ................................. 55
    BB Thakur, Smita Thakur
    Hypertension 55
    Pharmacologic Treatment 58
    Gestational Diabetes 61

11. Grey Areas in Diagnosis and Management of Hypertension .......... 67
    Anita Jaiswal
    Rule of Halves 67
    Types of Blood Pressure Instruments 70

SECTION 2 CARDIOLOGY

12. Atherosclerosis: Can We Tame it? .............................................. 75
    Harendra Kumar
    Methods are Carotid Intima-Media Thickness (CIMT) 75
    Cholesterol Absorption Inhibitor 77

13. Cardiac Cachexia ........................................................................ 80
    AKP Singh
    Pathophysiology 80
    Anabolic Failure 80
    Catabolic Activation 80
    Insulin Resistance 80
    Skeletal Muscle 81

    Santanu Guha, Bappaditya Kumar
    Management of Stable Coronary Artery Disease 82
    Indications for PCI 83
    Improvement in Survival with PCI 83
    Relief of Angina 83
    Patients without Clear Indications for Intervention 84

15. Newer Oral Anticoagulants in Clinical Practice ............................ 86
    Anshul Kumar Jain
    Comparison of NOACs with VKA 86
   Sameer Kumar, Girish MP, Mohit D Gupta
   What is the Debate? 90
   Risk Stratification 90
   Short-term versus Long Term DAPT: The Evidence So Far 91
   Duration of Dual Antiplatelet Therapy in Cases of Stable Coronary Artery Disease (CAD) After PCI 91
   Duration of Dual Antiplatelet Therapy in Patients Presenting with Acute Coronary Syndrome (ACS) 92
   Duration of DAPT in Patients Undergoing CABG 93
   Elective Noncardiac Surgery in Patients Treated with DAPT and PCI 93
   Switch Over Between Antiplatelets 94
   Special Circumstances 94

17. Newer Biomarkers in Heart Failure ........................................................................................ 97
   Saumitra Ray
   Diagnosis 97
   Other Biomarkers 98
   Biomarkers of HFpEF 98

18. Coronary Microvascular Dysfunction: An Update .................................................................... 100
   SM Mustafa Zaman
   Risk Factors and Pathophysiology 100
   Diagnosis 102
   Clinical Profile 102
   Treatment of Coronary Microvascular Dysfunction 104

   Nagendra Boopathy Senguttuvan
   Fractional Flow Reserve 110
   Characteristics of FFR 110
   Functional PCI 111
   Deferred PCI 112
   Assessment of Serial Lesions 112

20. Mega Trials in Cardiology ................................................................................................ 115
   Sundeep Mishra
   Hypertension Trials 115
   Secondary Prevention of CAD 116
   Hope Trial 116
   Arrhythmia 117
Heart Failure 117
Diabetes Mellitus 118

21. **Rheumatic Valvular Heart Disease** ................................................................. 121
   RR Singh
   Signs and Symptoms 121
   Mitral Stenosis 122
   Mitral Stenosis with Close-up on Mitral Valve 122
   Medical Treatment 124
   Surgical Treatment 124

22. **Advances in Management of Pulmonary Arterial Hypertension** ................................. 125
   Abhishek Gupta, S Ramakrishnan
   Current Epidemiology 125
   Management of PAH 125
   Newly Approved Medications for PAH 126
   Combination Therapy 127
   Nonpharmacological Options 128
   Stem Cell Therapy 128
   Lung Transplantation 128

23. **Infective Endocarditis: An Update** ........................................................................... 129
   Sudhir Varma, Samman Verma, Rommel Singh
   Changing Epidemiological Profile 129
   Diagnostic Issues 129
   Antimicrobial Therapy 129
   Complications 130
   Indications for Surgery 131
   Prevention 132

24. **Pregnancy and Heart Disease** ............................................................................... 133
   Gurleen Wander, Gurpreet Singh Wander
   Physiological Changes in Pregnancy 133
   Peripartum Cardiomyopathy 134
   Rheumatic Heart Disease 135
   Prosthetic Heart Valves 135
   Aortic Dissection 135
   Congenital Heart Disease 136
   General Principles of Management 136
   Intrapartum 136
25. A Review of Cardiorenal Syndrome ................................................................. 138
   Gurinder Mohan, Ranjeet Kaur, Aakash Aggarwal
   Pathophysiology  139
   Biomarkers in Cardiorenal Syndrome  140
   Management  141

26. Heart Failure with Reduced Ejection Fraction: Treatment Strategy ................. 144
   Amal Kumar Banerjee
   Classification  144
   Diagnosis  145
   Pharmacologic Treatment  147
   Nonsurgical Device Treatment  147
   Mechanical Circulatory Support and Heart Transplantation  148
   Heart Failure and Comorbidities  149
   Arrhythmias and Conductance Disturbances  149
   Monitoring  149

27. Pulmonary Embolism: Focus on New Drugs ..................................................... 151
   VK Katyal, Ashima Katyal, Naman Mukhi
   Pathophysiology  151
   Clinical Presentations  151
   Diagnosis  152
   Management of Acute Pulmonary Embolism  153

28. Echocardiographic Navigation of AF from Irregular Pulse to Slurring of the Speech: Relevance at All Stages in India and the Real World ........................................... 157
   HK Chopra, Ravi R Kasliwal, Manish Bansal, Shraddha Ranjan
   Echocardiographic Navigation in AF Management  158

SECTION 3 DIABETES

29. ADA Standards of Care: An Update ............................................................... 173
   Abhishek Pandey
   Section Changes  173
   Staging of Type 1 Diabetes  174
   Pharmacologic Therapy for Diabetes  175

30. Can Medical Care Change the Natural History of T2DM: Turning Fiction into Reality? .............. 181
   Rajesh Rajput
31. Are all Gliptins the Same: How to Decide and Choose? ................................................................. 186
   Harbir Kaur Rao, Rajinder Singh Gupta
   Pathogenesis of Type 2 Diabetes Mellitus  186
   Ideal Antihyperglycemic Drug  187
   Dipeptidyl Peptidase-4 Inhibitors  187
   Efficacy  188
   Safety  189

32. Diabetes and Inflammation ........................................................................................................... 191
   Jugal Kishor Sharma, Girish Khurana
   Link Between Diabetes and Inflammation  191
   Clinical Implications of Inflammation in Type-2 Diabetes  195
   Clinical Benefits Based on Inflammatory Theory  195
   Drugs Related to the Endoplasmic Reticulum Stress Theory  195

33. Pollution and Diabetes: Is there a Link? ....................................................................................... 198
   Brij Mohan
   Persistent Organic Pollutants  198
   Air Pollutants Sources  200

34. Musculoskeletal Manifestations of Diabetes Mellitus .................................................................... 203
   S Anita Nambiar, Divya G
   Limited Joint Mobility/ Rosenbloom Syndrome  203
   Adhesive Capsulitis of the Shoulder  204
   Dupuytren's Contracture/Disease  204
   Hyperostosis  204
   Carpal Tunnel Syndrome  204
   Flexor Tenosynovitis  205
   Neuroarthropathy (Charcot’s Joints)  205
   Diabetic Amyotrophy  205
   Osteoporosis  205
   Diabetic Muscle Infarction  205
   Reflex Sympathetic Dystrophy  206

35. How to Hold the HOLD? .............................................................................................................. 207
   NK Singh, Vaibhav Agnihotri, Richa Singh Agnihotri
   Prevalence  207
   Peculiarities of HOLD in India  207
   Mechanistic Characteristics  208
Behavioral Modification .................................................. 208
Physical Activity ............................................................... 209
Getting Rid of Persistent Organic Pollutants .................. 209
Pharmacological Interventions .......................................... 210

36. Dyslipidemia Management: Newer Avenues ................. 211
   Nirupam Prakash
   CETP Inhibitors .......................................................... 214

37. Metformin versus Insulin in Treatment of Gestational Diabetes Mellitus ........................................ 217
   Sandeep Garg, Onkar Awadhiya, Sunita Aggarwal
   Mechanism of Diabetes in pregnancy ......................... 217
   Diagnosis of GDM ...................................................... 217
   Glycemic Targets in GDM .......................................... 218
   Treatment Modalities of GDM .................................... 218
   Comparison of Insulin versus Metformin in GDM ..... 219

38. Early Initiation of Insulin Therapy in Diabetes Mellitus ...... 221
   Rajesh Kumar Jha, Sagar Dembla
   Concept and Evolution of Basal Insulin ...................... 221
   Role of Insulin in Treatment of Type 2 Diabetes Mellitus .. 222
   Benefits of Insulin Therapy in Diabetes Mellitus .......... 222
   Barriers to Basal Insulin in Type 2 Diabetes Mellitus ..... 222
   How to Start Insulin? .................................................. 223

39. Diabetic Complications in Indian Scenario: An Update .... 225
   Sidhartha Das, Santosh Kumar Swain, Saroj Kumar Tripathy
   Diabetes in India ......................................................... 225
   Complications in Type 2 DM ...................................... 226
   Macrovascular Complications .................................... 226
   Type 2 DM and Metabolic Syndrome ....................... 229
   Microvascular Complications in Type 2 DM .............. 229
   Diabetic Retinopathy ................................................. 230
   Diabetic Neuropathy and Diabetic Foot .................... 230
   Other Complications in Type-2 DM .......................... 232

40. GLP-1 Analogs: Benefits Beyond Glycemic Control ........ 238
   Rajeev Chawla, Shalini Jaggi
   GLP-1 Analogs .......................................................... 239
   Glycemic Efficacy of GLP-1 Receptor Agonists .......... 241
Extra Glycemic Benefits of GLP-1 Analogs 241
Weight Loss Associated with the Use of GLP-1 Receptor Agonists 242
Side Effects and Associated Risks of GLP-1 Receptor Agonists 243

41. Gliptins versus Sulfonylureas: Which is Better? ................................................................. 247
   V Palaniappan
   Importance of Glycemic Control in Curbing the Diabetes Burden 247
   DM in Elderly Recommendation 259
   Negative is not Absolutely Negative in SU Usage 261
   Points in Favor of SU 261

42. Metformin—the Molecule of the Decade: Old is Gold .......................................................... 262
   Sanjay Dash
   History 262
   Mechanism of Action 262
   Role of Metformin in T2DM 263
   Metformin and Body Weight 263
   Cancer Biology 264
   Adverse Drug Reactions and Contraindications 264

43. A Decade of RCTs in Diabetes: Clinical Implications .......................................................... 266
   Suhas Erande
   Prelude 266
   2007: What Did We Know? DCCT EDIC UKPDS 266
   2008: Tighter Glucose Control (?More Benefits) 266
   Impact of Recent CVOT in Diabetes on Practice 267
   Centrality of RCTS in Clinical Practice 267
   Importance of Clinical Practice Guidelines 268
   Factors which Influence Physician Practice 268
   Have RCTS in Diabetes Helped Clinical Practice in Last Decade? 269

44. Insulin Pumps in India .............................................................................................................. 270
   Narendra Pal Jain, Rishu Bhanot
   Insulin Pumps in Type 2 in India 270
   Types 271
   Indications for an Insulin Pump 271
   Current Scenario of Insulin Pumps in India 272
45. **Newer Insulins and Art of Insulin Therapy** ............................................................... 273
   Mangesh Tiwaskar
   Science of Insulin Therapy: The Need  273
   Insulins at a Glance  274
   Modes of Insulin Delivery  275
   Initiating Insulin Therapy  275
   Overcoming the Psychological Barriers to Insulin Therapy  277

46. **Individualization of Diabetes Care** ......................................................................... 281
   KK Pareek, Girish Mathur
   Treatment Approaches for T2 Diabetes  281
   Patient–Centered Approach  246
   Implementation Strategies  284
   Other Considerations  284
   Therapeutic Patient Education  285

47. **Diabetes and Immunity** ............................................................................................ 286
   Apurba Kumar Mukherjee, Indira Maisnam
   Immunity in the Pathogenesis of Diabetes Mellitus  286
   Defective Immune Response in Diabetes Mellitus  288

48. **Novel Therapeutic Approaches to Preserve Beta Cell Function in Diabetes Mellitus** 290
   Vijay Negalur
   Pancreatic Beta Cell Mass Function in Diabetes  290
   Therapeutic Approaches to Preserve Beta Cell Function in T1D  291
   Tumor Necrosis Factor-A (TNF-A) Agonist  293
   Therapeutic Approaches to Preserve Beta Cell Function in T2D  293

49. **Management of Diabetes in Resource Crunch Countries** ......................................... 299
   G Prakash
   Prevalence  299
   Challenges and the Way Ahead Epidemiological Data  299
   Screening  299
   Diabetes Management  300
   Diabetes Education  300
   Pharmacologic Management: Oral Antidiabetic Drugs  300

50. **Exercise Prescription for Lifestyle Diseases: A Cornerstone** ................................... 302
    Anil Kumar Virmani
    Lifestyle Diseases  302
51. Nonhigh–Density Lipoprotein Cholesterol: Primary Target for Lipid Lowering ............................. 305
    SN Narasingan
    Non-HDL-C as an Indicator of ASCVD Risk  305
    Other Advantages of Non-HDL-C  307

SECTION 4  ENDOCRINOLOGY

52. Growth Hormone Replacement Therapy: Current Recommendations ............................................. 313
    Minal Mohit
    Differences Between COGHD and AOGHD  314
    Consequences of Untreated GHD  314
    Metabolic Complications  314
    Osteopenia/Osteoporosis  314
    Quality of Life  315
    Transitional Care of GHD  315
    Diagnosis of GHD in Adults  315
    Factors Affecting GH Dosing  316
    Dosing Strategies  317
    Safety Issues with GH Replacement Therapy  318
    Unapproved Uses of GH in Adults  319

53. Vitamin D Therapy: Hope or Hype........................................................................................... 326
    PK Sasidharan
    Vitamin D Basic Facts  326
    Landmark Study on Vitamin D Deficiency  326
    Reasons for Widespread Deficiency of Vitamin D  327

54. Approach to a Patient with Short Stature ................................................................................. 333
    Indira Maisnam
    Physiology of Normal Growth  333
    Patterns of Normal Growth  333
    Diagnostic Approach to a Child with Short Stature  334

55. Logical Approach to Thyroid Nodule....................................................................................... 337
    KJ Shetty, KN Manohar
    Clinical Presentation  337
    Management  338
56. Primary Hypoparathyroidism and its Management................................................................. 341
   Ajay Aggarwal, Roopak Wadhwa
   Epidemiology 341
   Pathophysiology 341
   Signs and Symptoms 342
   Investigations 342
   Treatment 342

57. A New Look at Testosterone Therapy in Aging Males ....................................................... 344
   DC Sharma
   Changes in Reproductive Hormones with Age 344
   Effects of Decrease in Testosterone 344
   Suggested Approach 345

58. Lipohypertrophy Secondary to Insulin Injection Therapy ................................................. 347
   Sunil Gupta
   Prevalence 347
   Definition of Lipohypertrophy 347
   Causes of Lipohypertrophy 347
   Diagnosis 348
   Clinical Consequences of Lipohypertrophy 348
   Management 350

SECTION 5 NEUROLOGY

59. Headache: Headache for Physician...................................................................................... 355
   Gurubax Singh
   Every Head has its Own Headache 355
   First Severe Headache 355
   Chronic Daily Headache 356
   Headache in Elderly 357
   Status Migranosus 357
   Menstrual Migraine 357
   Headache with Comorbidities 357

60. Approach to Multiple Cranial Nerve Palsy........................................................................... 359
   K Mugundhan
   Intrinsic vs Extrinsic Brainstem Lesions 359
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>61. Nocturia: Evaluation and Management</td>
<td>363</td>
</tr>
<tr>
<td>Anish Kumar Gupta</td>
<td></td>
</tr>
<tr>
<td>Clinical Presentation</td>
<td>363</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>363</td>
</tr>
<tr>
<td>Treatment</td>
<td>365</td>
</tr>
<tr>
<td>Multidisciplinary Management</td>
<td>366</td>
</tr>
<tr>
<td>62. Neuromyelitis Optica: A Physician’s Perspective</td>
<td>367</td>
</tr>
<tr>
<td>Mrinal Kanti Roy, Sujoy Sarkar</td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td>367</td>
</tr>
<tr>
<td>63. First Seizure: Should or Should not be Treated?</td>
<td>371</td>
</tr>
<tr>
<td>PK Maheshwari, A Pandey, Akhilesh Kumar Singh</td>
<td></td>
</tr>
<tr>
<td>Importance of Multiple Seizures</td>
<td>371</td>
</tr>
<tr>
<td>Is There any Role of Antiepileptic Drug Prophylaxis?</td>
<td>371</td>
</tr>
<tr>
<td>When to Initiate Antiepileptic Drugs?</td>
<td>372</td>
</tr>
<tr>
<td>Seizure Recurrence</td>
<td>372</td>
</tr>
<tr>
<td>Approach to a Case of First Seizure</td>
<td>373</td>
</tr>
<tr>
<td>Management of First Seizure</td>
<td>374</td>
</tr>
<tr>
<td>64. An Overview and Practical Clinical Hints in the Diagnosis of Temporal Lobe Epilepsy</td>
<td>376</td>
</tr>
<tr>
<td>Venkataraman Nagrajan</td>
<td></td>
</tr>
<tr>
<td>Definition</td>
<td>376</td>
</tr>
<tr>
<td>Etiology</td>
<td>376</td>
</tr>
<tr>
<td>Pathology</td>
<td>376</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>376</td>
</tr>
<tr>
<td>Clinical Features</td>
<td>377</td>
</tr>
<tr>
<td>International Classification of the CPS</td>
<td>377</td>
</tr>
<tr>
<td>Seizure Phenomena</td>
<td>377</td>
</tr>
<tr>
<td>Eeg Phenomenon in TLE or CPS</td>
<td>378</td>
</tr>
<tr>
<td>Imaging Studies CT vs MRI</td>
<td>378</td>
</tr>
<tr>
<td>Differential Diagnosis</td>
<td>378</td>
</tr>
<tr>
<td>Management</td>
<td>379</td>
</tr>
<tr>
<td>Prognosis</td>
<td>379</td>
</tr>
<tr>
<td>65. Changing Scenario in Management of Status Epilepticus</td>
<td>380</td>
</tr>
<tr>
<td>Rajesh Shankar Iyer</td>
<td></td>
</tr>
<tr>
<td>Changing Definitions and Classification</td>
<td>380</td>
</tr>
<tr>
<td>New Terminologies</td>
<td>381</td>
</tr>
</tbody>
</table>
Super-refractory Status Epilepticus 382
Treatment of Super-refractory SE: An Update 382

66. Present Status of Thrombolysis in Acute Ischemic Stroke: Indian Scenario .......................... 386
   V Shankar
   Rates of Thrombolysis 386
   Thrombolysis Outcomes 386
   Thrombolysis Dosage 387
   Sonothrombolysis 387
   Tenecteplase 387
   Telestroke 387
   Complications and Other Observations 387
   Intraarterial TPA 388
   Thrombolysis and Endovascular Therapy 388

67. Immunomodulation in Neurological Disorders ................................................................. 389
   Man Mohan Mehndiratta, Ashish Duggal
   Central Nervous System Disorders 389
   Immunotherapy for MS Relapses 389
   Disease-modifying Immunotherapy for MS 392
   Myelin Oligodendrocyte Glycoprotein (MOG) Associated Demyelination 394
   Acute Disseminated Encephalomyelitis 395
   Primary Angiitis of CNS 398
   Disease Affecting the Peripheral Nervous System 398

68. Vertigo: Clinical Approach and Management ................................................................. 404
   Lakshmi Narasimhan Ranganathan, Thamil Pavai N,
   Guhan R, Arun Shivaraman MM, Mugundhan Krishnan
   Treatment of Vertigo 410

SECTION 6 GASTROENTEROLOGY/HEPATOLOGY

69. Acute Upper Gastrointestinal Bleeding ................................................................. 415
   Rajesh Upadhyay, Deepak Sharma
   Etiology 415
   Risk Factors 415
   Clinical Presentation 416
   Management 416
Medical Therapy 417
Endoscopic Therapy 417
Surgical Treatment 418
Angiographic Therapy 418
Prevention of Re-bleed 419

70. Acute Pancreatitis ........................................................................................................................... 421
G Loganathan, L Santhosh Vivekanadan
Etiopathogenesis 421
Clinical Features, Diagnosis and Severity Prediction 423
Management 426
Beyond the Early Phase 428
Prevention 432

71. The Gut Microbiota: A Forgotten Organ .......................................................................................... 436
Balvir Singh, Ram Prakash Pandey, Mridul Chaturvedi, TP Singh, Ashish Gautam
Composition of Gut Microbiota 436
Humans as Microbial Depots 436
Emergence of Microbiota 436
Gut Microbiota as an Organ 437
Link Between Gut Flora and Diseases 438
Future Hopes for Various Diseases 438

72. Nonalcoholic Fatty Liver Disease: Is it Really Benign? .................................................................... 442
AK Chauhan
NAFLD is a Progressive Condition 442
Role of Metabolic Risk Factors in Disease Progression 443
Pathophysiologic Link of Metabolic Risk Factors with HCC 443
Extrahepatic Complications of Nafld 444

73. Glucose Metabolism Disorders in Chronic Liver Disease .................................................................... 446
Aparna Agrawal, Prashasti Gupta
Role of Liver in Carbohydrate Metabolism 446
Glucose Metabolism in Diseased Liver 446
Mechanism of IR and GMD in CLD 446
Mechanism of LD in DM 447
Burden of GMD and IR in CLD and of LD in DM 447
Correlation of GMD with Etiology and Severity of CLD and Risk Factors of DM 447
Clinical Presentation of GMD in CLD 447
Implications of GMD on Complications of CLD 448
Diagnosis and Monitoring 448
Treatment of GMD in CLD 448
Results of Our Study 449

74. Hepatorenal Syndrome: Clinical Considerations ................................................................. 451
Tanuja Pravin Manohar
Definition 451
Epidemiology 451
Pathophysiology 451
Precipitating Factors 452
Diagnosis 453
Diagnostic Criteria for Hepatorenal Syndrome 453
Preventive Measures 453
Biomarkers in HRS 453
Treatment 453

75. Cirrhosis of Liver: Beyond Beta-blockers and Diuretics .................................................... 456
Anup K Das
Variceal Hemorrhage 456
Hepatorenal Syndrome (HRS) 457
Spontaneous Bacterial Peritonitis (SBP) 457

76. Hepatitis B: Are We Moving Ahead Towards Cure? ......................................................... 463
Anil C Anand
Epidemiology of HBV in India 463
The Virus 464
Immunopathogenesis 464
Natural History of HBV Infection 464
Management of Chronic HBV Infection and Innovative Approaches 465
Newer Drugs and Innovative Approaches 465

77. HIV/Hepatitis Coinfections ........................................................................................... 469
PK Agrawal
Epidemiology 469
Pathogenesis 469
Treatment 470
78. **Fecal Microbiota Transplantation: Current Indications and Methods** .......................................................... 472
L Ilavarasi, SS Lakshmanan

- Fecal Microbiota Transplantation Techniques 472
- Donor Selection 472
- History to be Obtained from the Donor 474
- Stool Evaluation 474
- Donor Blood Screening 474
- Donor Stool Preparation: European Consensus 2017 474
- Routes of Administration of FMT 474
- Clostridium Difficile Infections 474
- Inflammatory Bowel Disease 475
- Irritable Bowel Syndrome 475
- FMT in Obesity/Insulin Resistance and Diabetes 475
- FMT in Neurological Diseases 475
- Current and Future Directions 475

---

79. **Clinical Approach to a Patient of Dyspnea** ........................................................................................... 481
Alok Gupta, Rajat Gupta

- Mechanism 481
- Causes of Dyspnea 482
- Assessment Of Dyspnea 487
- History Taking 489
- Physical Examination 489
- Laboratory Studies 490
- Advanced Studies 491
- Management 493

80. **Syndrome Z** ........................................................................................................................................ 495
Devendra Prasad Singh

- OSA and Hypertension 495
- Obesity 495
Insulin Resistance 495
Pathophysiology of Syndrome Z 495
Diagnosis of Syndrome Z 497
OSA: Clinical Features 497
OSAs and Hypertension 497
Lifestyle Modifications 498

81. Asthma COPD Overlap Syndrome .......................................................... 500
Kashinath Padhiary
Definition 500
Incidence 500
Pathogenesis 501
Contributing Factors 501
Clinical Features 501
Diagnosis 501
Prognosis 502
Treatment 502

82. Global Warming and its Health Impact .............................................. 504
PS Shankar
Health Impact 504
Surface Temperature 504
El Nino 505
Ozone 505
Diseases 505
Future 506

83. ARDS: Recognition and Management ............................................. 508
Niteen D Karnik, Priya Bhate
Recognition 508
Diagnosis 508
Management 508

84. Clinical Approach to Solitary Pulmonary Nodule .................................. 514
BNBM Prasad
Definition 514
Causes 514
Prevalence 515
Approach to Diagnosis 515
Management 521
85. Challenges in the Management of CAP
Prashant Prakash, Akhilesh Kumar Singh
Definition of CAP 525
Epidemiology and Etiology 525
Diagnosis of CAP 525
Role of Microbiological Investigations in CAP 526
General Investigations and Risk Stratification Required in Patients with CAP 528
Antimicrobial Therapy in CAP 529

86. Air Pollution and its Health Impact
Vishal Chopra, Prabhleen Kaur, Siddharth Chopra
Mechanisms Leading to Health Effects 533
Types of Pollutants 534
Effects of Air Pollution on Different Organs 534

SECTION 8 INFECTIONS

87. Infections Causing Cancer
Anupam Dey
Pathogenesis 539
International Agency for Research on Cancer (WHO) Classification 539
Mechanisms by which Common Agents Cause Cancers 540
Detection and Proving Association of the Infectious Agent in Cancer 540

88. Transfusion Transmitted Infection
Apu Adhikary, Tuhin Santra
Human Immunodeficiency Virus 543
Hepatitis B virus 544
Hepatitis C virus 544
Malaria 544
Syphilis 544
Human T-Lymphotropic Virus I and II 544
Cytomegalovirus 545
Epstein–Barr virus 545
West Nile Virus 545
Parvovirus B19 545
Arboviruses 545
Bacterial infections 545
Other Infectious Agents  546
Pathogen Inactivation Technology  546
Donor Screening Questionnaire  546

89. Arboviral Infections: Is Effective Vaccination a Possible Solution? ................................................... 547
Ashok Kumar, Shubha Laxmi Margekar, Venugopal Margekar
Transmission  547
Clinical Findings and Epidemiology  548
Vaccination  548
Yellow Fever Vaccine  549
Japanese Encephalitis  549
Dengue Vaccine  550
Chikungunya Vaccine  551
Kyasanur Forest Disease  551
Crimean Congo Hemorrhagic Fever Virus  552

90. MDR-TB and XDR-TB: What are the Options? ....................................................................................... 553
Bidita Khandelwal
Epidemiology  553
Defining MDR-, Pre-XDR- and XDR-TB  553
Management Options in M/XDR-TB  553
Regimes  554
Newer Drugs Options  554
High-Dose Isoniazid  555
Duration of Treatment M/XDR-TB  555
Surgical Options  555

91. Acute Encephalitis: Indian Scenario ........................................................................................................... 556
Debasis Chakrabarti, Shankha S Sen
Etiology  556
Epidemiology  556

92. Tropical Fever: A Case-based Approach .................................................................................................. 562
Manoranjan Behera, Sidhartha Das, Jayant Kumar Panda
Specific Infections  564
Investigation Strategy  566
Treatment Strategy  566
93. **Vivax Malaria: No Longer Benign!**

K Nagesh
- Epidemiology 570
- Malaria Parasite 571
- Vivax Malaria 571
  - Malignant Behavior of *Plasmodium Vivax* 572
- Pathophysiology 573
- Clinical Features 573
- Clinical Classifications 573
- Management 574
  - Treatment of Malaria in Pregnancy 574
- Clinical Malaria 575

94. **Newer Modalities in Diagnosis of Tuberculosis**

Prem Parkash Gupta
- Direct Sputum Smear Microscopic Examination 576
- Culture-Based Methods for the Diagnosis of Tuberculosis 576
- Rapid Detection of Drug Resistance: In-house Methods 577
- Colorimetric Redox Indicator Methods 578
- Diagnosis of TB Based on DNA Tools 578
- Latent Tuberculous Infection Diagnosis 580

95. **Resurgence of Yellow Fever: A Great Challenge**

Rajib Ratna Chaudhary
- Transmission of Yellow Fever Virus 583
- Pathogenesis 584
- Clinical Presentation 584
- Laboratory Finding 584
- Differential Diagnosis 585
- Treatment and Prevention 585
- Prognosis 585

96. **Complicated Dengue**

Rajeev Gupta
- Introduction to Dengue 586
- Hepatic Complications 587
97. **Scrub Typhus: Need for Alert** ................................................................. 588
   Raman Sharma, Sunil Mahavar, Mayank Gupta
   - Etiology 588
   - Epidemiology and Transmission 588
   - Clinical Manifestations 589
   - Diagnosis 590
   - Differential Diagnosis 590
   - Treatment 590
   - Prevention 591

98. **Pyrexia of Unknown Origin: Current Concept** ........................................ 592
   SV Ramana Murty, Chakravarthy DJK
   - Epidemiology 592

99. **Approach to a Patient of Meningitis** .......................................................... 600
   Sanjiv Maheshwari, Vijay Prakash Hawa
   - Clinical Presentation 600
   - Examination 601
   - Investigation 602
   - CSF Examination 602
   - Other Laboratory Studies 603
   - Neuroimaging 603
   - Treatment 603

100. **Leptospirosis: What We Should Know?** ...................................................... 604
    Shantanu Kumar Kar, Paluru Vijayachari, Jayant Kumar Panda
    - Epidemiology 604
    - Clinical Presentation 605
    - Diagnosis 605
    - Treatment and Prevention 606

101. **Kala-azar Elimination in India** ................................................................. 607
    Shyam Sundar

102. **Sickle Cell Crisis: How to go Forward?** ..................................................... 610
    Srikant Kumar Dhar
    - How to Diagnose? 610
    - How to Manage? 610
    - Principles of Management 611
    - Analgesia 611
Contents

Fluid Replacement 611
Treatment of Acute Chest Syndrome 611
Recommendations for Vaccination 613

103. Do Not Rash When Fever Coincides with Rash ................................................................. 614
Sriprasad Mohanty
Approach to Diagnosis 614
Viral hemorrhagic Fevers 615

104. Disseminated Intravascular Coagulation: Management Updates ................................. 617
Puneet Saxena, Aradhna Sharma, Madhulata Agarwal, Sher Singh Dariya, Hitesh Sharma
Pathogenesis 617
Diagnosis 618
Differential Diagnosis 619
Treatment 620

105. Adult Immunization: Current Scenario in India ............................................................... 622
Prasanta Kumar Bhattacharya, Subrahmanya Murti V
Hepatitis B Vaccine 622
Hepatitis A Vaccine 624
Diphtheria, Pertussis and Tetanus Vaccines 624
Measles, Mumps and Rubella Vaccine 624
Varicella and Zoster (Shingles) Vaccines 624
Pneumococcal Vaccine 625
Meningococcal Vaccine 625
Haemophilus Influenzae Vaccine 626
Human Papilloma Virus Vaccine 626
Influenza Vaccine 626
Japanese Encephalitis Vaccine 626
Yellow Fever Vaccine 626
Cholera Vaccine 626
Typhoid Vaccine 626
Newer Vaccines 627

106. H1N1 Influenza: 9 Years' Journey in Gujarat ................................................................. 629
Asha N Shah
History of Reassortment Events in the Evolution of the 2009 Influenza A (H1N1) Virus 629
Government of India Guidelines on Categorization of Seasonal Influenza A H1N1 Cases
(Revised on 11-2-2015) 630
Cytokine Storm in Young 632
107. Ebola ................................................................................................................... ........................................... 636
   Rajeev Raina, Nidhi Raina
   Background 636
   Transmission 636
   Clinical Symptoms 638
   Diagnosis 639
   Treatment and Vaccines 639
   Lessons Learnt 639

SECTION 9 HUMAN IMMUNODEFICIENCY VIRUS

108. 90-90-90 Strategy in HIV Epidemic ....................................................................................... ................... 645
   R Sajith Kumar
   Treatment Target 645
   Reaching Target 1 648
   Reaching Target 2 648
   Reaching Target 3 649
   Ending the AIDS Epidemic 650

109. ART in HIV Infection: State-of-the-Art .................................................................................. ................... 652
   BB Rewari, Manish Bamrotiya, Suman Singh
   Antiretroviral Therapy for HIV Infection 652
   Goals of Antiretroviral Therapy 652
   Clinical Pharmacology of Commonly used ARV Drugs 653
   Considerations before Initiation of ART 654
   Recommended Choice of First Line Regimen 656
   Monitoring of Patients on ART 656
   Treatment Failure: When to Change and What to Change 658

110. Opportunistic Infections in HIV: Changing Scenario .......................................................... 660
   Amar R Pazare
   Common Opportunistic Infections in HIV-infected Patients in the Past 660

111. Neurological Manifestations of HIV ...................................................................................... ................... 663
   Dipanjan Bandyopadhyay, Amit Adhikary
   Acute Seroconversion Illness 663
   Direct Viral Invasion 663
   Myelopathy due to HIV 663
Peripheral Neuropathy 664
Opportunistic Infections Affecting the CNS 664
Progressive Multifocal Leukoencephalopathy 666
HIV Associated Malignancies Affecting the CNS 666
Neurological Disease Arising from ART 666

112. Cardiopulmonary Manifestations of HIV ................................................................. 667
   Alaka K Deshpande
   Pericardial Disease 667
   Cardiotoxic Drugs 668
   Coronary Artery Disease 668
   Pulmonary Manifestations 669
   Bacterial Infections 669
   Fungal Infections 670
   Malignant Neoplasms 670

113. Immune Reconstitution Inflammatory Syndrome ...................................................... 671
   Vinay Rampal
   Background 671
   Definition 671
   Clinical Factors Associated with the Development of IRIS 672
   Mycobacterium Tuberculosis IRIS 673
   Atypical Mycobacterial IRIS 674
   Cytomegalovirus Infection IRIS 674
   Varicella Zoster Virus Infection IRIS 675
   Cryptococcus Neoformans Infection IRIS 675
   Other Etiologies 676

SECTION 10 INTENSIVE CARE UNIT

114. Critical Care Toxicology: Update 2018 ................................................................. 681
   Omender Singh, Deven Juneja
   Initial Resuscitation and Management 681
   Laboratory Investigations 682
   Decontamination 682
   Enhanced Elimination 682
115. Hypoglycemia in ICU ................................................................. 684
    Sundaram Arulrhaj, Aarathy Kannan, Manikandan R, Vinodh Kumar A
    Classification of Hypoglycemia 684
    Pathogenesis of Hypoglycemia in ICU 684
    Acute Coronary Syndrome 690

116. Biomarkers in Sepsis ............................................................. 695
    Virendra Kumar Goyal, Mohit Goyal
    C-reactive Protein 697
    Biomarker Combinations 698
    Statement of UNMET Need 698

117. Early and Empiric Antibiotics in Sepsis: Current Controversy .................... 700
    Trupti H Trivedi
    Future Therapy 703

118. Arterial Blood Gas Analysis: Simple Steps for Understanding .................... 705
    Ravindra Kumar Das
    Collection of Blood Samples and Transportation 705
    Method of Analysis 705
    Case History/Provisional Diagnosis 710

119. Superbugs in ICU and the Need for Antibiotic Stewardship .......................... 716
    Pankaj Kumar

120. Perioperative Management in Diabetes .............................................. 720
    Pramod Kumar Sinha
    Risks of Poor Diabetic Control 720
    Factors Causing Adverse Outcome 720
    Metabolic Response to Surgery and Anesthesia and the Effect of Diabetes 721
    Principles and Target of Perioperative Management 721
    Preoperative Measures 721
    Intraoperative Management 722
    Measures During Surgery 722
    Postoperative Management 724

121. Hospital Acquired Infections ...................................................... 725
    Piyush Jain
    Nosocomial Pneumonia 725
    Diagnosis 726
Causative Organisms 726
Treatment 726
Preventive Measures 727
Nosocomial Urinary Tract Infections 727
Diagnosis 727
Treatment 727
Catheter Related Blood Stream Infection 728
Diagnosis 728
Treatment 728
Nosocomial Surgical Site and Soft Tissue Infection 728
Management 729

SECTION TOXICOLOGY

122. Clinical Approach to Patient of Coma ..................................................................................... 733
   Geeta Kampani, Umashankar US, Munish Prabhakar
   Etiology and Pathogenesis 733
   Assessment of COMA 733
   History 733
   General Physical Examination 733
   Neurologic Examination 734
   Brainstem Reflexes 735
   Respiratory Patterns 735
   Investigations 735
   Prognosis 736

123. Common Poisoning and Management ......................................................................................... 737
   Saurabh Srivastava
   Aluminium Phospide Poisoning (Celphos Poisoning) 737
   Mechanism of Toxicity 737
   Clinical Features of Intoxication 737
   Organophosphate Poisoning 738
   Mechanism of Toxicity 738
   Clinical Features 738
   Management 739
   Corrosive Poisoning 739
   Mechanism of Injury 739
Clinical Presentation 739
Management 740
Rodenticides 740
Zinc Phosphide 740
Anticoagulants 740
Kerosene Oil 740
Clinical Features of Intoxication 740
Management 740
Benzodiazepines 740
Clinical Features of Intoxication 740
Management 741

124. Management of Snake Bite in India ....................................................................................... 742
Shibendu Ghosh, Prabuddha Mukhopadhyay
Snake Bite Prevention and Occupational Risk 744
Preventative Measures 744
Diagnosis Phase 744
General Signs and Symptoms of Viperine Envenomation 744
Late-onset Envenoming 747
Diagnosis Phase: Investigations 747
Management of Snake Bite in General 747
Handling Tourniquets 748
ASV Administration Criteria 748
Prevention of ASV Reactions: Prophylactic Regimes 749
Neurotoxic Envenomation 751
Recovery Phase 751
AntiHemostatic Maximum ASV Dosage Guidance 752

SECTION 12 HEMATOLOGY/ONCOLOGY

125. Stem Cell Therapy in Various Diseases: Dawn of a New Era ..................................................... 759
Sunita Aggarwal, Jahnvi Dhar, Sandeep Garg
Stem Cell 759
Methods for Stem Cells Transplantation 759
Hematopoietic Stem Cell Transplantation (HSCT) 759
Scope of Stem Cell Therapy in India 761
126. Basics of Hematopoietic Stem Cell Transplant: Autologous and Allogeneic ................................... 763
Punit L Jain
Principles of HSCT 763

127. Clinical Approach to Patient with Purpuric Spot ................................................................. 767
Chanchal Kumar Jana, Gaurab Bhaduri
Pathophysiology 767
Causes of Nonpalpable Purpura 767
Causes of Palpable Purpura 768
Clinical Approach to Purpuric Spots 768
Case Studies 768
Diagnosis: Henoch–Schönlein Purpura 768
Diagnosis: Purpura Fulminans 769
Management of Some Common Causes of Purpura 769

128. Thrombocytosis: Clinical Approach .................................................................................... 772
Sudhir Mehta, Laxmi Kant Goyal, Shaurya Mehta, Gunja Jain
Regulation of Thrombopoiesis 772
Causes of Thrombocytosis 773
Clinical Features 775
Differential Diagnosis 775
Treatment 776

129. Macrophage Activation Syndrome .................................................................................... 7778
Taran Kumar Dutta, Tony Kadavanu, Arunkumar Ramachandrappa
Epidemiology 778
Etiopathogenesis and Triggers 778
Clinical Features 778
Laboratory Features 779
Diagnostic Criteria 781
Further Approach 781
Differential Diagnosis 781
Management 781
Biologicals 782

130. Hemotransfusion Therapy: Boon or Bane? ......................................................................... 784
Anil Kumar Gupta
Hemotherapy: A Precious Tool for Humans 784
Hemotherapy, Inherent Risks 785
131. Idiopathic CD4 Lymphocytopenia ................................................................. 788
   Bhupendra Gupta, Harpreet Singh
   Pathogenesis  788
   Clinical Manifestations  788
   Infections  788
   Evaluation  789
   Diagnosis  789
   Treatment  790
   Other Treatment Modalities  790
   Prognosis  790

132. Hepatocellular Carcinoma: Surveillance, Diagnosis and Management .......... 791
   Kirti Shetty
   Background  791
   Surveillance Strategy  791
   Target Population  791
   Tests  791
   Diagnosis  792
   Tissue Diagnosis  792
   Staging  792
   Treatment  792
   Surgical Therapies for HCC  793

133. Approach to a Patient with Polycythemia .................................................... 795
   Mathew Thomas
   Introduction, Definitions and Classification  795
   Mechanisms  795
   Major Causes of Polycythemia  796
   Initial Evaluation of Patients with Polycythemia  796
   Physical Examination  797
   Systemic Examination  797
   Laboratory Investigations  797
   Further Diagnostic Approach  797
   Further Evaluation  797
   Diagnosis of Polycythemia Vera  798
   Treatment of Polycythemia Vera  798
   Management of Secondary Polycythemia  800
134. Immunotherapy: A New Weapon in Cancer Treatment ................................................................. 801
   Vineet Talwar, Venkata Pradeep Babu K
   Oncolytic Viruses in Immunotherapy  801
   Vaccines in Immunotherapy  802
   Adoptive Cell Therapy  802
   Immune Check Point Blockade  802

135. Metronomic Chemotherapy in Metastatic Malignancies: A New Concept ............................ 805
   Ankur Bahl
   Metronomic Chemotherapy Versus Conventional Chemotherapy  805
   Angiogenesis–Chemotherapy Model  806
   Activation of Immunity  806
   Rational of Various Drugs Used in Metronomic Chemotherapy  806
   Metronomic Chemotherapy in Adult Cancers  807
   Toxicity of Metronomic Chemotherapy  807

S E C T I O N 13

136. Asymptomatic Hyperuricemia: What to Do? .............................................................................. 811
   Arup Kumar Kundu, Shyamashis Das
   Epidemiology  811
   Definitions  811
   Why Hyperuricemia Occurs?  811
   Clinical Consequences of Persistent Hyperuricemia  812
   Evaluation of Patients with Asymptomatic Hyperuricemia  813
   When to Treat Asymptomatic Hyperuricemia?  813

137. Polyarteritis Nodosa: An Enigma ................................................................................................. 815
   Ghan Shyam Pangtey, Paramjeet Singh
   Case Vignette  815
   Introduction  816
   Epidemiology  817
   Clinical Features  817
   Laboratory Evaluation and Imaging  818
   Prognosis  818
   Management  819
138. Chikungunya Arthritis................................................................................................... 821
    Harpreet Singh, Neeraj Kumar

139. Clinical Approach to a Patient with Vasculitis ........................................................... 825
    N Subramanian
    Pathogenesis 825
    Classification 825
    Clinical Features 825
    Investigations 827
    Management 827
    Practical Points 828

140. Osteoporosis Screening, Prevention, and Treatment .................................................. 830
    Tanu Shweta Pandey
    Osteopenia 830

SECTION 14 Nephrology

141. Recipient and Donor Selection for Renal Transplantation in India: Current Status .............. 837
    Sanjay Kumar Agarwal
    Advantages of Renal Transplant over Maintenance Dialysis 837
    Contraindication of Renal Transplantation 837
    Recipient Evaluation 837
    Donor Evaluation 839

142. Rituximab: Panacea of Glomerular Diseases .................................................................. 842
    Dipankar M Bhowmik, N Rajkanna
    Primary Glomerular Diseases 843
    Glomerular Diseases that Cause Nephrotic Syndrome: Immune Complex 843
    Secondary Glomerular Diseases 844
    Adverse Effects of Rituximab 844

143. ABO-Incompatible Kidney Transplantation ...................................................................... 846
    Dinesh Khullar, Sagar Gupta
    Historical Perspective 846
    ABO Antigens and Blood Groups 847
    Pathogenesis 847
    Accommodation 847
Techniques of Desensitization  847
Complications  848

144. Prevention and Management of Diabetic Kidney Disease ................................................................. 849
Pritam Gupta, Rajesh Aggarwal, Blessy Sehgal
Spectrum of Renal Involvement in Diabetes Mellitus (Type 2)  849
Risk Factors for the Development of Diabetic Nephropathy  849
Management of Microalbuminuria in Diabetes  851
Screening for Diabetic Kidney Disease  851
Other Biochemical Markers  851
Natural History of Type I Diabetic Nephropathy  851
Treatment Target  851
What is Optimal Target HBA1C?  852
Blood Pressure Control  852
Blockade of Renin Angiotensin System  852
Treatment of Dyslipidemia in Diabetic Nephropathy  853
Emerging and Future Therapies  853

145. Anemia in Chronic Kidney Disease: Management .................................................................................. 854
HK Aggarwal, Deepak Jain, Rahul Chauda
Anemia in Chronic Kidney Disease: Management  854
Diagnosis and Evaluation  854
Treatment  854
Erythropoiesis Stimulating Agents  855
Blood Transfusion  856
Other Therapies  856
Option in Future  857

SECTION 15 GERIATRICS AND GENETIC

146. Geriatric Teaching Indian Relevance ....................................................................................................... 861
OP Sharma
Ageing  861
Medical Infrastructure  862
Geriatrics Services  862
Need v/s Availability  863
Need Based Solutions  863
147. Therapeutic Uses of Human Endothelial Progenitor Cells ................................................................. 865
   Ananda Bagchi, Aradhya Sekhar Bagchi
   Isolation of EPC  866
   Therapeutic Uses of EPC  866
   EPCs and Cardiovascular Risk factors  866
   EPC and Atherosclerotic Cardiovascular Disease  867
   EPCs and Cardiovascular Trials  868
   Effect of Cardiac Drugs on EPCs  868
   ACE Inhibitors and Angiotensin II Receptor Blockers  868
   CD34 Antibody Coated Stents  868
   Uses of EPCs in Diabetes Mellitus  869
   Role of EPCs in Tumor Growth  869
   Role EPCs in Endometriosis  869
   Uses of EPCs in Wound Healing  869
   Uses of EPCs in Peripheral Arterial Obstructive Disease  870

148. Management of Gender Dysphoric Persons, Sex Change Surgeries
       and Our (Indian) Experience ..................................................................................................................... 872
       Richie Gupta, Rajat Gupta

149. Anemia in Elderly: Experience at a Large Tertiary Center .............................................................. 876
       PS Ghalaut, Ragini Ghalaut
       Classification of Anemia  876
       Diagnosis of a Case with Anemia in Elderly  878
       Investigations in Anemia in Elderly  878
       Management of Anemia in Elderly  880
       Indications of Blood Transfusion  881

SECTION 16  SOCIAL ISSUES

150. Medical Ethics ........................................................................................................................................ 885
       Hem Shanker Sharma
       Theories of Medical Ethics  885
       Governing Bodies and Rules  887
151. **Soul and Spiritual Health** ................................................................. 888

SP Yoganna

- Origin and Evolution of Universe—Matter and Energy theory (Big Bang Theory) 888
- Natural Principles of Universe 888
- Human is a Manifestation of Universal Energy 889
- Human Being is the Miniature of the Universe 889
- Human Being is Holistic 889
- PreProgrammed Evolution and Human Body Functions 890
- Life Energies 894
- Soul (Atma) 895
- Ways of Acquiring Spiritual Energy 897
- God and God Men 898
- What is Spiritual Health? 899
- Diagnostic Approach 899

152. **Cooking Oils: Which to Use?** ............................................................. 901

Sonia Arora, Vitull K Gupta, Meghna Gupta

- Composition of Fats 901
- Trans Fatty Acids or Partially Hydrogenated Fatty Acids 902
- What are Cooking Oils? 903
- Choosing the Right Oil 904
- Why Blends are Needed? 905

153. **IT Solution in Regulation of Medical Education and Medical Practice** ........................................ 906

Ajay Kumar

154. **Changing Trends in Medicine: Past, Present and Future** ................................. 909

Pritam Gupta, Ghan Shyam Pangtey, Sujata Mangla

- Medicine Before the 20th Century 909
- Medicine in the 20th Century 911
- Medical Science and Technology in 21st Century 913
- Future Medical Inventions 915
155. Isoniazid Preventive Therapy: Operational Guidelines ................................................................. 918

Mohanjeet Kaur, Ashish Chawla

TB and HIV  918
HIV-TB Collaborative Activities  918
Single Window Services  918
Isoniazid Preventive Therapy  919
Why INH for IPT?  920
Evaluation of the Patients (Before Starting IPT)  920
Regimen Plan for IPT  920
Concomitant Use of IPT with ART  920
Can Co-Trimoxazole be Dispensed with IPT?  920
Drug Resistance with IPT  921

156. Hypnotherapy in Medical Disorders ......................................................................................... 922

Rajeev Mohan Kaushik

Areas of the Brain Affected by Hypnosis  922
Physiological Effects of Hypnosis  923
Factors Affecting Therapeutic Response  923
Types of Hypnosis  923
Applications of Hypnotherapy in Medical Disorders  924
Hypnoanalysis  925
Prospects  925

157. An Approach to Recurrent Falls in the Elderly ........................................................................ 926

S Ramnathan Iyer, Revati R Iyer

158. Ultrasonography in Critically Ill Patients .................................................................................. 929

Sameer Gulati, Bhupendra Gupta

Equipment  929
Procedure: Lung Ultrasonography  929
Procedure: Compression Ultrasonography for Deep Vein Thrombosis  931
Procedure: Bedside Ocular Ultrasound  931
Procedure: Focused Echocardiography  932
Procedure: Screening Abdominal Ultrasonography  933
Ultrasonography in Trauma  933
Advantages and Limitations  934
159. Imaging Parameters in Pulmonary Thromboembolism ................................................................. 935
   Priya Jagia, Niraj Nirmal Pandey
   Diagnosis of Pulmonary Embolism and Deep Venous Thrombosis 935
   Imaging Modalities 935
   Assessment of Pulmonary Embolism Severity and Prognostication 937
   Diagnostic Algorithm in a Patient of Suspected PE 939

Index ............................................................................................................................................. 941